Inify Laboratories has signed for 11,620 sq ft at Milton Park’s Nebula development.
The Swedish digital pathology and AI cancer diagnostics company’s new facility brings its clinical, laboratory and commercial functions together in a single building.
Kate Bucknall, managing director of Inify UK, said: “Our new base at Milton Park is a real milestone in our mission to improving cancer care and reducing delays in patient pathways. Our recent success shows that digitised, AI-supported workflows can halve the time from biopsy to diagnosis, which has been transformative for both patients and clinicians in Sweden.”
Bucknall added: “After an extensive search, we chose Milton Park based on its vibrant community, strong transport links and access to exceptional talent near Oxford and London. Nebula was also ideal for us to build a state-of-the-art lab from scratch. The buildings’ eco-friendly credentials, timber frame and light-filled design aligns with our Scandinavian aesthetic and sustainability approach.
“The new space is welcoming, for both the Inify team and also for our clinicians and partners. From wellbeing events and sense of community to transport connections, the park is somewhere we feel people will want to come to work.”
Tom Booker, commercial manager at MEPC Milton Park, said: “We’re thrilled that Inify has chosen Milton Park as its UK home. The team’s decision to join the Milton Park community reinforces our position as a home for leading life science and med-tech organisations to collaborate, innovate and grow. Inify’s work in Sweden is a real example of how innovation can deliver meaningful impact in healthcare. We look forward to seeing the difference it can make on patient outcomes in its new UK base here at Milton Park.”
